Study and analysis of the use of bevacizumab in the treatment of breast cancer

This study aimed to explore the application of bevacizumab in breast cancer treatment. We reviewed the research progress and current status of bevacizumab, analyzed its mechanism of action, and introduced protein expression analysis to further investigate its therapeutic effect. Bevacizumab is an angiogenesis inhibitor that prevents tumor growth by binding to and blockingvascular endothelial growth factor (VEGF). Data were obtained derived from the United States Society of Clinical Oncology (ASCO), which employed reversed-phase protein array technology (RPPA) to analyze the expression levels of related proteins. This included data on 210 proteins from 55 CTx samples and 54 Bev + CTx samples. We conducted a follow-up analysis based on the existing studies of nine protein signatures with corresponding beta coefficients identified by Lasso regression. However, only the first eight proteins were analyzed due to insufficient data. Additionally, we analyzed four of the 210 proteins with high expression levels. Statistical analysis revealed differences in protein the expression levels between the CTx and Bev + CTx groups, though these differences were not statistically significant. Clustering results displayed protein expression data through heat maps, revealing a clustering relationship among several proteins. This study provides a reference for the application of bevacizumab in breast cancer treatment.